Guidance and quality standards awaiting development | Guidance

Showing 231 to 240 of 410

Guidance and quality standards awaiting development
Title	Type
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [ID6706]	Technology appraisal guidance
Osimertinib for adjuvant treatment of EGFR mutation-positive stage 1A2 or 1A3 non-small-cell lung cancer after complete tumour resection	Technology appraisal guidance
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]	Technology appraisal guidance
Pain management (young people and adults)	Quality standard
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]	Technology appraisal guidance
Palbociclib with anti-HER2 and endocrine therapies for maintenance treatment of hormone-receptor positive HER2-positive metastatic breast cancer [ID6251]	Technology appraisal guidance
Pancreatitis (including acute pancreatitis)	Quality standard
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]	Technology appraisal guidance
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]	Technology appraisal guidance
Pelabresib with ruxolitinib for treating myelofibrosis [TSID12391]	Technology appraisal guidance